Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
News|Articles|October 27, 2025
Sarah McLeod, PhD, breaks down high cure rates with zoliflodacin for uncomplicated gonorrhea
Author(s)Joshua Fitch, Senior Editor , Sarah McLeod, PhD
Fact checked by: Joshua Fitch, Senior Editor
Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in this Q&A with Contemporary Pediatrics.
Advertisement
Advertisement
New subgroup analyses from the global phase 3 zoliflodacin trial highlight the drug’s efficacy against multidrug-resistant Neisseria gonorrhoeae, including ciprofloxacin-resistant strains, across all infection sites and patient subgroups. The data were presented at
Related to this article
Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.
The latest IDSA histoplasmosis update adds a consensus statement on severe disease and outlines when children with pulmonary infection warrant itraconazole therapy.
This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
Advertisement
Advertisement